Targeted therapy before surgery for HER2-positive lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted drug (SHR-A1811) combined with an immunotherapy drug (adebelimumab) before surgery for patients with early-stage, resectable lung cancer that has a specific HER2 alteration. The goal is to shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stage II or III non-small cell lung cancer that can be surgically removed.
- Your tumor has a specific HER2 alteration (a genetic change) confirmed by biopsy.
- You have not received prior cancer treatment (like radiation, chemotherapy, or immunotherapy) for this cancer.
- You are in good general health (ECOG score 0 or 1) and have adequate organ function.
- You are willing to use highly effective contraception during and for 180 days after the study, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, adebrelimab and trastuzumab rezetecan, for people with stage III lung cancer that cannot be removed by surgery and has a specific genetic change called HER2. The goal is to see if this combination shrinks tumors and helps patients live longer.
This trial tests whether adding adebrelimab (an immunotherapy drug) to standard chemotherapy before surgery can shrink non-small cell lung cancer that can be removed. The goal is to improve the chance of successful surgery and reduce the risk of the cancer coming back.
This trial tests two new drugs—SHR-A1921 and adebrelimab—for people with advanced non-small cell lung cancer (NSCLC) whose cancer has grown after standard first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests an investigational drug called SHR-1826 for people with non-small cell lung cancer that has spread or cannot be removed by surgery. It aims to see if the drug can shrink tumors and improve outcomes.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests an investigational drug called SHR-A1811 in people with non-small cell lung cancer that has spread or cannot be removed by surgery and has a HER2 alteration. The goal is to see if the drug is effective and safe for this type of cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.